Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe SepsisSteven M. Opal, for the ACCESS Study Group, Mark Tidswell et al.|JAMA|2013Cited by 797
Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis*Mark Tidswell, Steven M. Opal, Janice L. Wheeler et al.|Critical Care Medicine|2009Cited by 226